These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
130 related articles for article (PubMed ID: 33633048)
21. Clinical impact and predictors of complete ST segment resolution after primary percutaneous coronary intervention: A subanalysis of the ATLANTIC Trial. Fabris E; van 't Hof A; Hamm CW; Lapostolle F; Lassen JF; Goodman SG; Ten Berg JM; Bolognese L; Cequier A; Chettibi M; Hammett CJ; Huber K; Janzon M; Merkely B; Storey RF; Zeymer U; Cantor WJ; Tsatsaris A; Kerneis M; Diallo A; Vicaut E; Montalescot G Eur Heart J Acute Cardiovasc Care; 2019 Apr; 8(3):208-217. PubMed ID: 28841028 [TBL] [Abstract][Full Text] [Related]
22. Optimal P2Y12 Inhibitor in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: A Network Meta-Analysis. Rafique AM; Nayyar P; Wang TY; Mehran R; Baber U; Berger PB; Tobis J; Currier J; Dave RH; Henry TD JACC Cardiovasc Interv; 2016 May; 9(10):1036-46. PubMed ID: 27198684 [TBL] [Abstract][Full Text] [Related]
23. Cangrelor in combination with ticagrelor provides consistent and potent P2Y12-inhibition during and after primary percutaneous coronary intervention in real-world patients with ST-segment-elevation myocardial infarction. Mohammad MA; Andell P; Koul S; James S; Scherstén F; Götberg M; Erlinge D Platelets; 2017 Jun; 28(4):414-416. PubMed ID: 27885888 [TBL] [Abstract][Full Text] [Related]
24. A comparison of cangrelor, prasugrel, ticagrelor, and clopidogrel in patients undergoing percutaneous coronary intervention: A network meta-analysis. Westman PC; Lipinski MJ; Torguson R; Waksman R Cardiovasc Revasc Med; 2017 Mar; 18(2):79-85. PubMed ID: 28089137 [TBL] [Abstract][Full Text] [Related]
25. Cangrelor for ST-Segment-Elevation Myocardial Infarction. Erlinge D Circulation; 2019 Apr; 139(14):1671-1673. PubMed ID: 30933619 [No Abstract] [Full Text] [Related]
26. A Woman in Her 80s With Anterior ST-Elevation Myocardial Infarction and Shock. Motazedian P; Le May MR; Glover C; Hibbert B Chest; 2017 Jan; 151(1):e5-e8. PubMed ID: 28065257 [No Abstract] [Full Text] [Related]
27. Double Infarction after Acute Multivessel Coronary Artery Occlusion. Kafkas N; Dragasis S; Georgopoulos S; Floros G Hellenic J Cardiol; 2017; 58(1):89-92. PubMed ID: 28163149 [No Abstract] [Full Text] [Related]
28. Acute Coronary Syndrome With ST-Segment Elevation in Inferior Leads: Is It Always Right? Kapil A; Thakur A; Yadav S JAMA Intern Med; 2021 Aug; 181(8):1110-1111. PubMed ID: 34180941 [No Abstract] [Full Text] [Related]
29. Safety and Tolerability of Transitioning from Cangrelor to Ticagrelor in Patients Who Underwent Percutaneous Coronary Intervention. Badreldin HA; Carter D; Cook BM; Qamar A; Vaduganathan M; Bhatt DL Am J Cardiol; 2017 Aug; 120(3):359-361. PubMed ID: 28576266 [TBL] [Abstract][Full Text] [Related]
30. Impact of oral P2Y12 inhibitors on residual thrombus burden and reperfusion indexes in patients with ST-segment elevation myocardial infarction. Di Vito L; Versaci F; Limbruno U; Pawlowski T; Gatto L; Romagnoli E; Cattabiani MA; Micari A; Trivisonno A; Marco V; Prati F J Cardiovasc Med (Hagerstown); 2016 Sep; 17(9):701-6. PubMed ID: 27467458 [TBL] [Abstract][Full Text] [Related]
31. Periprocedural Outcomes According to Timing of Clopidogrel Loading Dose in Patients Who Did Not Receive P2Y Abtan J; Ducrocq G; Steg PG; Stone GW; Mahaffey KW; Gibson CM; Hamm CW; Price MJ; Prats J; Deliargyris EN; White HD; Harrington RA; Bhatt DL Circ Cardiovasc Interv; 2019 Mar; 12(3):e007445. PubMed ID: 30871355 [TBL] [Abstract][Full Text] [Related]
32. Rationale and design of the Cangrelor versus standard therapy to acHieve optimal Management of Platelet InhibitiON PHOENIX trial. Leonardi S; Mahaffey KW; White HD; Gibson CM; Stone GW; Steg GW; Hamm CW; Price MJ; Todd M; Dietrich M; Gallup D; Liu T; Skerjanec S; Harrington RA; Bhatt DL Am Heart J; 2012 May; 163(5):768-776.e2. PubMed ID: 22607853 [TBL] [Abstract][Full Text] [Related]
33. Identification of the culprit artery in inferior myocardial infarction through the 12-lead ECG. Ruiz-Mateos B; García-Borbolla R; Nunez-Gil I; Almendro-Delia M; Vivas D; Seoane-García T; Cristo-Ropero MJ; Izquierdo-Bajo A; Madrona-Jimenez L; Fernandez-Ortiz A; Hidalgo-Urbano R; Ibanez B; Garcia-Rubira JC Coron Artery Dis; 2020 Jan; 31(1):20-26. PubMed ID: 31169552 [TBL] [Abstract][Full Text] [Related]
34. Facilitation Through Aggrastat or Cangrelor Bolus and Infusion Over PrasugreL: a MUlticenter Randomized Open-label Trial in PatientS with ST-elevation Myocardial InFarction Referred for PrimAry PercutaneouS InTERvention (FABOLUS FASTER) Trial: Design and Rationale : The FABOLUS FASTER Trial. Gargiulo G; Esposito G; Cirillo P; Nagler M; Minuz P; Campo G; Gragnano F; Manavifar N; Piccolo R; Avvedimento M; Tebaldi M; Wahl A; Hunziker L; Billinger M; Heg D; Windecker S; Valgimigli M J Cardiovasc Transl Res; 2021 Feb; 14(1):110-119. PubMed ID: 32096064 [TBL] [Abstract][Full Text] [Related]
35. Time-dependent benefits of pre-treatment with new oral P2Y Pepe M; Cafaro A; Paradies V; Signore N; Addabbo F; Bortone AS; Navarese EP; Contegiacomo G; Forleo C; Bartolomucci F; Di Cillo O; Bianchi FP; Zanna D; Favale S Catheter Cardiovasc Interv; 2019 Mar; 93(4):592-601. PubMed ID: 30269413 [TBL] [Abstract][Full Text] [Related]
36. Association between gender and short-term outcome in patients with ST elevation myocardial infraction participating in the international, prospective, randomised Administration of Ticagrelor in the catheterisation Laboratory or in the Ambulance for New ST elevation myocardial Infarction to open the Coronary artery (ATLANTIC) trial: a prespecified analysis. Venetsanos D; Sederholm Lawesson S; Alfredsson J; Janzon M; Cequier A; Chettibi M; Goodman SG; Van't Hof AW; Montalescot G; Swahn E BMJ Open; 2017 Sep; 7(9):e015241. PubMed ID: 28939567 [TBL] [Abstract][Full Text] [Related]
37. Platelet inhibition with standard vs. lower maintenance dose of ticagrelor early after myocardial infarction (ELECTRA): a randomized, open-label, active-controlled pharmacodynamic and pharmacokinetic study. Kubica J; Adamski P; Buszko K; Barańska M; Sikora J; Marszałł MP; Sobczak P; Sikora A; Kuliczkowski W; Fabiszak T; Kubica A; Jilma B; Alexopoulos D; Navarese EP Eur Heart J Cardiovasc Pharmacother; 2019 Jul; 5(3):139-148. PubMed ID: 30689800 [TBL] [Abstract][Full Text] [Related]
38. Reduced immediate ischemic events with cangrelor in PCI: a pooled analysis of the CHAMPION trials using the universal definition of myocardial infarction. White HD; Chew DP; Dauerman HL; Mahaffey KW; Gibson CM; Stone GW; Gruberg L; Harrington RA; Bhatt DL Am Heart J; 2012 Feb; 163(2):182-90.e4. PubMed ID: 22305835 [TBL] [Abstract][Full Text] [Related]
39. Investigator-Reported Bleeding Versus Post Hoc Adjudication of Bleeding: Lessons From the CHAMPION PHOENIX Trial. Jatene T; Harrington RA; Stone GW; Steg PG; Gibson CM; Hamm CW; Price MJ; Prats J; Deliargyris EN; Mahaffey KW; White HD; Bhatt DL; J Am Coll Cardiol; 2016 Feb; 67(5):596-8. PubMed ID: 26846956 [No Abstract] [Full Text] [Related]
40. Effects of Fentanyl Versus Morphine on Ticagrelor-Induced Platelet Inhibition in Patients With ST-Segment Elevation Myocardial Infarction: The PERSEUS Randomized Trial. Iglesias JF; Valgimigli M; Carbone F; Lauriers N; Giorgio Masci P; Degrauwe S Circulation; 2020 Dec; 142(25):2479-2481. PubMed ID: 33347326 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]